BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28025101)

  • 21. Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma.
    Syed N; Chavan S; Sahasrabuddhe NA; Renuse S; Sathe G; Nanjappa V; Radhakrishnan A; Raja R; Pinto SM; Srinivasan A; Prasad TS; Srikumar K; Gowda H; Santosh V; Sidransky D; Califano JA; Pandey A; Chatterjee A
    Proteomics; 2015 Jan; 15(2-3):383-93. PubMed ID: 25327479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. cRGD peptide installation on cisplatin-loaded nanomedicines enhances efficacy against locally advanced head and neck squamous cell carcinoma bearing cancer stem-like cells.
    Miyano K; Cabral H; Miura Y; Matsumoto Y; Mochida Y; Kinoh H; Iwata C; Nagano O; Saya H; Nishiyama N; Kataoka K; Yamasoba T
    J Control Release; 2017 Sep; 261():275-286. PubMed ID: 28666729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC).
    Zhang F; Li Y; Zhang H; Huang E; Gao L; Luo W; Wei Q; Fan J; Song D; Liao J; Zou Y; Liu F; Liu J; Huang J; Guo D; Ma C; Hu X; Li L; Qu X; Chen L; Yu X; Zhang Z; Wu T; Luu HH; Haydon RC; Song J; He TC; Ji P
    Oncotarget; 2017 Feb; 8(8):12968-12982. PubMed ID: 28099902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells.
    Zenzmaier C; Kern J; Heitz M; Plas E; Zwerschke W; Mattesich M; Sandner P; Berger P
    Exp Cell Res; 2015 Nov; 338(2):162-9. PubMed ID: 26410556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SOX8 regulates cancer stem-like properties and cisplatin-induced EMT in tongue squamous cell carcinoma by acting on the Wnt/β-catenin pathway.
    Xie SL; Fan S; Zhang SY; Chen WX; Li QX; Pan GK; Zhang HQ; Wang WW; Weng B; Zhang Z; Li JS; Lin ZY
    Int J Cancer; 2018 Mar; 142(6):1252-1265. PubMed ID: 29071717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
    Boerrigter G; Burnett JC
    Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin.
    Fetz V; Bier C; Habtemichael N; Schuon R; Schweitzer A; Kunkel M; Engels K; Kovács AF; Schneider S; Mann W; Stauber RH; Knauer SK
    Int J Cancer; 2009 May; 124(9):2033-41. PubMed ID: 19130609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats.
    Reinke Y; Gross S; Eckerle LG; Hertrich I; Busch M; Busch R; Riad A; Rauch BH; Stasch JP; Dörr M; Felix SB
    Eur J Pharmacol; 2015 Nov; 767():1-9. PubMed ID: 26407652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Butyrate response factor 1 enhances cisplatin sensitivity in human head and neck squamous cell carcinoma cell lines.
    Lee SK; Kim SB; Kim JS; Moon CH; Han MS; Lee BJ; Chung DK; Min YJ; Park JH; Choi DH; Cho HR; Park SK; Park JW
    Int J Cancer; 2005 Oct; 117(1):32-40. PubMed ID: 15880358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
    Hagege A; Ambrosetti D; Boyer J; Bozec A; Doyen J; Chamorey E; He X; Bourget I; Rousset J; Saada E; Rastoin O; Parola J; Luciano F; Cao Y; Pagès G; Dufies M
    Theranostics; 2021; 11(19):9571-9586. PubMed ID: 34646387
    [No Abstract]   [Full Text] [Related]  

  • 32. A Novel Sirtuin-3 Inhibitor, LC-0296, Inhibits Cell Survival and Proliferation, and Promotes Apoptosis of Head and Neck Cancer Cells.
    Alhazzazi TY; Kamarajan P; Xu Y; Ai T; Chen L; Verdin E; Kapila YL
    Anticancer Res; 2016 Jan; 36(1):49-60. PubMed ID: 26722027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells.
    Wiechec E; Hansson KT; Alexandersson L; Jönsson JI; Roberg K
    Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of apoptosis and sensitization of head and neck squamous carcinoma cells to cisplatin by targeting survivin gene expression.
    Khan Z; Tiwari RP; Khan N; Prasad GB; Bisen PS
    Curr Gene Ther; 2012 Dec; 12(6):444-53. PubMed ID: 22974420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
    Huang Z; Li H; Huang Q; Chen D; Han J; Wang L; Pan C; Chen W; House MG; Nephew KP; Guo Z
    Mol Carcinog; 2014 Oct; 53(10):777-86. PubMed ID: 23661500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting acid ceramidase sensitises head and neck cancer to cisplatin.
    Roh JL; Park JY; Kim EH; Jang HJ
    Eur J Cancer; 2016 Jan; 52():163-72. PubMed ID: 26687835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of HDAC6 Protein Enhances Bortezomib-induced Apoptosis in Head and Neck Squamous Cell Carcinoma (HNSCC) by Reducing Autophagy.
    Chang I; Wang CY
    J Biol Chem; 2016 Aug; 291(35):18199-209. PubMed ID: 27369083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancer.
    Zerp SF; Stoter TR; Hoebers FJ; van den Brekel MW; Dubbelman R; Kuipers GK; Lafleur MV; Slotman BJ; Verheij M
    Radiat Oncol; 2015 Jul; 10():158. PubMed ID: 26223311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
    Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM
    Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular pathways in the chemosensitization of cisplatin by quercetin in human head and neck cancer.
    Sharma H; Sen S; Singh N
    Cancer Biol Ther; 2005 Sep; 4(9):949-55. PubMed ID: 16082193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.